Cladribine tablets and multiple sclerosis: NICE technology appraisal

被引：0

作者：

Gaber, Tarek ^{[1
]}

Shippen, Clare ^{[2
]}

机构：

[1] Wrightington Wigan & Leigh NHS Fdn Trust, Neurol Rehabil, Wigan, England

[2] North West Deanery, Rehabil Med, Manchester, Lancs, England

来源：

PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2018年 / 22卷 / 01期

关键词：

D O I：

10.1002/pnp.486

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.(1) An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.

引用

页码：5 / 6

页数：2

共 50 条

[31] Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study
Rauma, Ilkka
Viitala, Matias
Kuusisto, Hanna
Atula, Sari
Sipila, Jussi O. T.
Ryytty, Mervi
Soilu-Hanninen, Merja
Jarvinen, Elina
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 61
[32] Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar
Canibano, Beatriz Garcia
Okar, Lina
Baniamer, Yahya Zakarya
Deleu, Dirk
CLINICAL NEUROLOGY AND NEUROSURGERY, 2024, 247
[33] European experience of cladribine tablets in elderly multiple sclerosis: Could it be the last treatment ?
de Seze, Jerome
Zecca, Chiara
Castelnovo, Giovanni
Ayrignac, Xavier
Patrick, Vermersch
Gobbi, Claudio
Claudia, Mallucci
Dalliere, Clarisse Carra
Pierre, Labauge
Bigaut, Kevin
Laurent, Kremer
Collongues, Nicolas
Lanotte, Livia
Thouvenot, Eric
Ernon, Christine
Dive, Dominique
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 344 - 345
[34] Late stage clinical development plan for cladribine tablets in the treatment of multiple sclerosis
Viglietta, V.
Greenberg, S.
Mikol, D.
Weiner, J.
Alteri, E.
Chang, P.
Krumwieh, D.
Musch, B.
JOURNAL OF NEUROLOGY, 2010, 257 : S143 - S144
[35] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Clavelou, Pierre
Castelnovo, Giovanni
Pourcher, Valerie
De Seze, Jerome
Vermersch, Patrick
Ben-Amor, Ali-Frederic
Savarin, Carine
Defer, Gilles
NEUROLOGY AND THERAPY, 2023, 12 (05) : 1457 - 1476
[36] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
Giovannoni, Gavin
Mathews, Joela
NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595
[37] COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
Jack, Dominic
Damian, Doris
Nolting, Axel
Galazka, Andrew
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 51
[38] Danish experience with cladribine tablets in the treatment of relapsing multiple sclerosis: a nationwide study
Sorensen, P. S.
Heick, A.
Petersen, T.
Joensen, H.
Kopp, T. I.
Sellebjerg, F.
Magyari, M.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 165 - 165
[39] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Pierre Clavelou
Giovanni Castelnovo
Valérie Pourcher
Jerome De Sèze
Patrick Vermersch
Ali-Frederic Ben-Amor
Carine Savarin
Gilles Defer
Neurology and Therapy, 2023, 12 : 1457 - 1476
[40] Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program
Cook, S.
Leist, T.
Comi, G.
Montalban, X.
Sylvester, E.
Hicking, C.
Dangond, F.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 305 - 306

← 1 2 3 4 5 →